{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:42:27Z","timestamp":1768891347122,"version":"3.49.0"},"reference-count":104,"publisher":"Baishideng Publishing Group Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJH"],"published-print":{"date-parts":[[2014]]},"DOI":"10.4254\/wjh.v6.i6.370","type":"journal-article","created":{"date-parts":[[2014,7,3]],"date-time":"2014-07-03T01:52:51Z","timestamp":1404352371000},"page":"370","source":"Crossref","is-referenced-by-count":64,"title":["Management of cytomegalovirus infection and disease in liver transplant recipients"],"prefix":"10.4254","volume":"6","author":[{"given":"Jackrapong","family":"Bruminhent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"ref1","unstructured":"Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes 2004;11:77-86."},{"key":"ref2","unstructured":"Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 2003;10:60-65."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 2007;13:1703-1709.","DOI":"10.1002\/lt.21280"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Gane E, Saliba F, Valdecasas GJ, O’Grady J, Pescovitz MD, Lyman S, Robinson CA. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 1997;350:1729-1733.","DOI":"10.1016\/S0140-6736(97)05535-9"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00382.x"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2007.00220.x"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Paya CV, Hermans PE, Wiesner RH, Ludwig J, Smith TF, Rakela J, Krom RA. Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations. J Infect Dis 1989;160:752-758.","DOI":"10.1093\/infdis\/160.5.752"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1086\/339329"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1086\/375194"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Singh N, Wagener MM. Strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2006;144:456-457; author reply 457.","DOI":"10.7326\/0003-4819-144-6-200603210-00024"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20417"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 2005;62:S7-S13.","DOI":"10.1093\/ajhp\/62.suppl_1.S7"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1086\/324516"},{"key":"ref14","unstructured":"Razonable RR, Paya CV. Infections and allograft rejection - intertwined complications of organ transplantation. Swiss Med Wkly 2005;135:571-573."},{"key":"ref15","unstructured":"O’Grady JG, Alexander GJ, Sutherland S, Donaldson PT, Harvey F, Portmann B, Calne RY, Williams R. Cytomegalovirus infection and donor\/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet 1988;2:302-305."},{"key":"ref16","unstructured":"Noack KB, Wiesner RH, Batts K, van Hoek B, Ludwig J. Severe ductopenic rejection with features of vanishing bile duct syndrome: clinical, biochemical, and histologic evidence for spontaneous resolution. Transplant Proc 1991;23:1448-1451."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Ludwig J, Wiesner RH, Batts KP, Perkins JD, Krom RA. The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation. Hepatology 1987;7:476-483.","DOI":"10.1002\/hep.1840070311"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2001.22040"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Madalosso C, de Souza NF, Ilstrup DM, Wiesner RH, Krom RA. Cytomegalovirus and its association with hepatic artery thrombosis after liver transplantation. Transplantation 1998;66:294-297.","DOI":"10.1097\/00007890-199808150-00003"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0b013e3282f0d386"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1086\/514340"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1086\/317929"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Dockrell DH, Prada J, Jones MF, Patel R, Badley AD, Harmsen WS, Ilstrup DM, Wiesner RH, Krom RA, Smith TF. Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. J Infect Dis 1997;176:1135-1140.","DOI":"10.1086\/514104"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Mendez J, Espy M, Smith TF, Wilson J, Wiesner R, Paya CV. Clinical significance of viral load in the diagnosis of cytomegalovirus disease after liver transplantation. Transplantation 1998;65:1477-1481.","DOI":"10.1097\/00007890-199806150-00012"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Razonable RR, Rivero A, Brown RA, Hart GD, Espy MJ, van Cruijsen H, Wilson J, Groettum C, Kremers W, Smith TF. Detection of simultaneous beta-herpesvirus infections in clinical syndromes due to defined cytomegalovirus infection. Clin Transplant 2003;17:114-120.","DOI":"10.1034\/j.1399-0012.2003.02104.x"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21266"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Humar A, Kumar D, Raboud J, Caliendo AM, Moussa G, Levy G, Mazzulli T. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002;2:461-466.","DOI":"10.1034\/j.1600-6143.2002.20511.x"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Rosen HR, Chou S, Corless CL, Gretch DR, Flora KD, Boudousquie A, Orloff SL, Rabkin JM, Benner KG. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997;64:721-726.","DOI":"10.1097\/00007890-199709150-00010"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1086\/342911"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Singh N, Husain S, Carrigan DR, Knox KK, Weck KE, Wagener MM, Gayowski T. Impact of human herpesvirus-6 on the frequency and severity of recurrent hepatitis C virus hepatitis in liver transplant recipients. Clin Transplant 2002;16:92-96.","DOI":"10.1034\/j.1399-0012.2002.1o096.x"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2002.32282"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182472876"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/lt.22146"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1086\/528718"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000226071.12562.1a"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003774.pub2"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005;143:870-880.","DOI":"10.7326\/0003-4819-143-12-200512200-00005"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1086\/507337"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Portela D, Patel R, Larson-Keller JJ, Ilstrup DM, Wiesner RH, Steers JL, Krom RA, Paya CV. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995;171:1014-1018.","DOI":"10.1093\/infdis\/171.4.1014"},{"key":"ref40","unstructured":"Winston DJ, Imagawa DK, Holt CD, Kaldas F, Shaked A, Busuttil RW. Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection. Transplantation 1995;60:1357-1360."},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Malek SK, Obmann MA, Gotoff RA, Foltzer MA, Hartle JE, Potdar S. Campath-1H induction and the incidence of infectious complications in adult renal transplantation. Transplantation 2006;81:17-20.","DOI":"10.1097\/01.tp.0000189713.14993.db"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1086\/510388"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060068"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995;346:69-74.","DOI":"10.1016\/S0140-6736(95)92110-9"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Sarmiento JM, Dockrell DH, Schwab TR, Munn SR, Paya CV. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 2000;14:136-138.","DOI":"10.1034\/j.1399-0012.2000.140206.x"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2008.03.084"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01063.x"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1086\/514339"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Kang SH, Abdel-Massih RC, Brown RA, Dierkhising RA, Kremers WK, Razonable RR. Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation. J Infect Dis 2012;205:639-646.","DOI":"10.1093\/infdis\/jir819"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.00797.x"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"de Rooij BJ, van der Beek MT, van Hoek B, Vossen AC, Rogier Ten Hove W, Roos A, Schaapherder AF, Porte RJ, van der Reijden JJ, Coenraad MJ. Mannose-binding lectin and ficolin-2 gene polymorphisms predispose to cytomegalovirus (re)infection after orthotopic liver transplantation. J Hepatol 2011;55:800-807.","DOI":"10.1016\/j.jhep.2011.01.039"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1086\/523652"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Giulieri S, Manuel O. QuantiFERON(R)-CMV assay for the assessment of cytomegalovirus cell-mediated immunity. Expert Rev Mol Diagn 2011;11:17-25.","DOI":"10.1586\/erm.10.109"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02618.x"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31829df29d"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis993"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Warlé MC, Farhan A, Metselaar HJ, Hop WC, van der Plas AJ, Kap M, de Rave S, Kwekkeboom J, Zondervan PE, IJzermans JN. In vitro cytokine production of TNFalpha and IL-13 correlates with acute liver transplant rejection. Hum Immunol 2001;62:1258-1265.","DOI":"10.1016\/S0198-8859(01)00321-4"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Fietze E, Prösch S, Reinke P, Stein J, Döcke WD, Staffa G, Löning S, Devaux S, Emmrich F, von Baehr R. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation 1994;58:675-680.","DOI":"10.1097\/00007890-199409000-00007"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00216-06"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Hooks MA, Perlino CA, Henderson JM, Millikan WJ, Kutner MH. Prevalence of invasive cytomegalovirus disease with administration of muromonab CD-3 in patients undergoing orthotopic liver transplantation. Ann Pharmacother 1992;26:617-620.","DOI":"10.1177\/106002809202600501"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03618.x"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Singh N, Gayowski T, Wagener MM, Marino IR. Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis. Transplantation 1996;61:402-406.","DOI":"10.1097\/00007890-199602150-00014"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)02350-3"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1086\/425905"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2005.10.014"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1086\/339449"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005;79:85-90.","DOI":"10.1097\/01.TP.0000146844.65273.62"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial. Transplantation 2000;70:717-722.","DOI":"10.1097\/00007890-200009150-00002"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20676"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1002\/lt.23460"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1111\/tri.12101"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12103"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.02026.x"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2009.00974.x"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(05)66553-1"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21362"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Caliendo AM, St George K, Kao SY, Allega J, Tan BH, LaFontaine R, Bui L, Rinaldo CR. Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients. J Clin Microbiol 2000;38:2122-2127.","DOI":"10.1128\/JCM.38.6.2122-2127.2000"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Razonable RR, Paya CV, Smith TF. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J Clin Microbiol 2002;40:746-752.","DOI":"10.1128\/JCM.40.3.746-752.2002"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2003.12.010"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit096"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Singh N, Wannstedt C, Keyes L, Wagener MM, Gayowski T, Cacciarelli TV. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years. Transplantation 2005;79:1428-1434.","DOI":"10.1097\/01.TP.0000157867.98649.F5"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000040601.60276.96"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Razonable RR, Paya CV. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Expert Rev Anti Infect Ther 2004;2:27-41.","DOI":"10.1586\/14787210.2.1.27"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, O’Grady J, Robinson C, To Z, Wren K. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000;44:2811-2815.","DOI":"10.1128\/AAC.44.10.2811-2815.2000"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1002\/lt.23530"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04231.x"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005129.pub2"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00391.x"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Freeman RB, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Heaton N. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 2004;78:1765-1773.","DOI":"10.1097\/01.TP.0000142619.01510.A5"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03074.x"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG, Abramowicz D, Ives JA, Farhan M, Peeters P. Extended valganciclovir prophylaxis in D+\/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010;90:1427-1431.","DOI":"10.1097\/TP.0b013e3181ff1493"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients. Transplant Proc 2005;37:3182-3186.","DOI":"10.1016\/j.transproceed.2005.07.032"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2009.06.005"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318200b9f0"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002;35:866-872.","DOI":"10.1086\/342385"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Limaye AP. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients. Semin Respir Infect 2002;17:265-273.","DOI":"10.1053\/srin.2002.36447"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181e94106"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(11)70024-x"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2013.01.082"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1128\/aac.05983-11"},{"key":"ref101","unstructured":"Mommeja-Marin HBT, Chittick G. Demographic\/Baseline Characteristics of Patients Treated with CMX001 for Serious or Life-threatening Double-stranded DNA (dsDNA) Virus Infections: Predictors of Multiple dsDNA virus Infection. Europeon group for blood and marrow transplantation meeting London: UK; 2013;."},{"key":"ref102","unstructured":"Chemaly RFEG, Champlin R, Richard M, Zimmermann H, Lischka P, Stoelben S, McCormick D, Ruebsamen-Schaeff H. Letermovir (AIC246) for the Prevention of CMV Infections Meets Primary Endpoint in Phase 2b Trial in Human Blood Precursor Cell Transplant Recipients. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA: United States; 2012;."},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03530.x"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"Razonable RR. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol 2008;14:4849-4860.","DOI":"10.3748\/wjg.14.4849"}],"container-title":["World Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1948-5182\/full\/v6\/i6\/370.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T22:51:31Z","timestamp":1598050291000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1948-5182\/full\/v6\/i6\/370.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":104,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.4254\/wjh.v6.i6.370","relation":{},"ISSN":["1948-5182"],"issn-type":[{"value":"1948-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}